Skip to main content
. 2025 May 16;25:710. doi: 10.1186/s12879-025-11101-3

Table 2.

Clinical symptoms of ATBL in the hematogenous dissemination group and the non- hematogenous dissemination group

Clinical Symptoms Hematogenous Dissemination group (n = 75) Non-hematogenous Dissemination group (n = 103) P
Asymptomatic 1 (1.3%) 6 (5.8%) 0.241
Abdominal pain 41 (54.7%) 66 (64.1%) 0.205
Abdominal distension 20 (26.7%) 45 (43.7%) 0.020
Diarrhea 5 (6.7%) 14 (13.6%) 0.140
Hematochezia 1 (1.3%) 6 (5.8%) 0.241
Constipation 0 (0.0%) 2 (1.9%) 0.510
Increased frequency of defecation 0 (0.0%) 1 (1.0%) 1.000
Rectal tenesmus 0 (0.0%) 2 (1.9%) 0.510
The changes of character of stool 1 (1.3%) 4 (3.9%) 0.399
Intestinal obstruction 0 (0.0%) 1 (1.0%) 1.000
Fever 26 (34.7%) 28 (27.2%) 0.284
Loss of appetite 18 (24.0%) 16 (15.5%) 0.156
Night sweat 10 (13.3%) 17 (16.5%) 0.560
Weak 12 (16.0%) 8 (7.8%) 0.086
Loss of weight 8 (10.7%) 5 (4.9%) 0.141
Cough and sputum production 21 (28.0%) 16 (15.5%) 0.043
Breathless 6 (8.0%) 2 (1.9%) 0.071
Chest pain 2 (2.7%) 2 (1.9%) 1.000
Tightness in the chest 0 (0.0%) 1 (1.0%) 1.000
Nausea and vomiting 3 (4.0%) 7 (6.8%) 0.522
Headache 2 (2.7%) 0 (0.0%) 0.176
Dizzy 1 (1.3%) 0 (0.0%) 0.421
Superficial lymph node enlargement 5 (6.7%) 0 (0.0%) 0.012
Abdominal mass 1 (1.3%) 1 (1.0%) 1.000

ATBL, abdominal tuberculous lymphadenopathy